GlassScriptPhysician profile
Elizabeth Holcomb
NPI 1194111385
$2,203.75
in general payments reported to CMS, 2019-2025
17 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $494 · 2022: $128 · 2023: $543 · 2024: $851 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.43 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $519.51 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $453.90 | 2021-2024 | |
| Gilead Sciences, INC. | $284.54 | 2023-2024 | Epclusa |
| Janssen Pharmaceuticals, INC | $260.58 | 2021-2025 | Invega |
| Alkermes, INC. | $140.44 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Supernus Pharmaceuticals, INC. | $139.34 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $98.92 | 2023 | Austedo Xr |
| Braeburn INC. | $67.43 | 2024-2025 | Brixadi |
| Lilly USA, LLC | $38.68 | 2024-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $34.47 | 2023-2024 | Pifeltro, Delstrigo, Dificid |
| Theratechnologies INC. | $30.75 | 2024-2025 | Egrifta, Trogarzo |
| Neurocrine Biosciences, INC. | $29.78 | 2023 | Ingrezza |
| Lundbeck LLC | $28.86 | 2024 | Rexulti |
| Viiv Healthcare Company | $23.41 | 2025 | Apretude |
| Corium, LLC | $20.15 | 2024 | Azstarys |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $16.51 | 2023 | Symtuza |
| Emd Serono, INC. | $16.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Holcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.